Legal & General Group PLC Poseida Therapeutics, Inc. Transaction History

Legal & General Group PLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	SELL	$2.37 - $9.6 $251 - $1,017	-106 Reduced 1.6%	6,514 $62,000
Q3 2024 Feb 28, 2025	BUY	$2.7 - $4.04 $286 - $428	106 Added 1.63%	6,620 $18,000
Q2 2024 May 29, 2025	BUY	$2.0 - $3.46 $960 - $1,660	480 Added 7.82%	6,620 $19,000
Q2 2024 Aug 14, 2024	BUY	$2.0 - $3.46 $960 - $1,660	480 Added 7.82%	6,620 $19,000
Q1 2024 May 29, 2025	BUY	$2.76 - $4.13 $16,946 - $25,358	6,140 New	6,140 $19,000

Q4 2023 May 29, 2025	BUY	$1.83 - $3.51 $11,236 - $21,551	6,140 New	6,140 $20,000
Q4 2023 Feb 15, 2024	SELL	$1.83 - $3.51 $752 - $1,442	-411 Reduced 6.27%	6,140 $20,000
Q2 2023 Aug 14, 2023	BUY	$1.66 - $3.4 $10,874 - $22,273	6,551 New	6,551 $11,000
Q2 2022 Aug 22, 2022	SELL	$1.87 - $5.0 $4,319 - $11,550	-2,310 Closed	0 $0
Q2 2021 Aug 12, 2021	SELL	$7.96 - $10.07 $8,541 - $10,805	-1,073 Reduced 31.72%	2,310 $23,000
Q1 2021 May 17, 2021	BUY	$8.51 - $11.91 $16,313 - $22,831	1,917 Added 130.76%	3,383 $32,000
Q3 2020 Nov 13, 2020	BUY	$8.09 - $16.25 $11,859 - $23,822	1,466 New	1,466 $13,000

5.34M

Ticker PSTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,775,600
Market Cap $815M
Description
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.